sr141716 has been researched along with Diabetes Mellitus, Type 2 in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 53 (84.13) | 29.6817 |
| 2010's | 10 (15.87) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, JH; Kim, KW; Kim, W; Park, JY; Rho, JG; Seong, JK; Shin, H; Son, DH; Yoon, SH | 1 |
| Choi, JM; Jin, SM; Kim, JH; Kim, KW; Lee, S; Oh, BJ; Park, CY; Park, SW; Yang, SJ | 1 |
| Baretić, M | 1 |
| Dopart, R; Kendall, DA; Lu, D | 1 |
| Barnett, A; Rahim, A; Samat, A | 1 |
| Seissler, J | 1 |
| Paquot, N; Scheen, AJ | 2 |
| Noll, G; Périat, D; Sudano, I | 1 |
| Chatterjee, T; Ince, H; Nienaber, ChA; Rehders, TC; Ritz, A | 1 |
| Chevalier, S; Hollander, P; Iranmanesh, A; Rosenstock, J | 1 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V | 1 |
| Paquot, N; Scheen, AJ; Van Gaal, LF | 1 |
| Golay, A | 1 |
| Davies, MJ; Jarvis, J; Khunti, K; Srinivasan, BT | 1 |
| Després, JP | 3 |
| Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET | 1 |
| Scheen, AJ | 3 |
| Amod, A; Chaudhari, U; Hollander, PA; Litwak, LE | 1 |
| Patti, ME | 1 |
| Bocquier, A; Bouvenot, G; Bouvenot, J; Cortaredona, S; Jardin, M; Nauleau, S; Sauze, L; Sciortino, V; Verger, P | 1 |
| Cha, DR; Cha, JJ; Han, JY; Han, KH; Han, SY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Kim, SH; Lee, JE; Lee, MH; Nam, DH; Song, HK | 1 |
| Colman, E | 1 |
| Bunce, S; Heppenstall, C; Smith, JC | 1 |
| Kennedy, RL; Khoo, EY | 1 |
| Kordella, T | 1 |
| Vinik, AI | 1 |
| Tonstad, S | 1 |
| Lebovitz, H | 1 |
| Cannon, CP; Gelfand, EV | 1 |
| Cleland, SJ; Sattar, N | 1 |
| Finer, N; Hollander, P; Jensen, MD; Scheen, AJ; Van Gaal, LF | 1 |
| Hollander, P | 1 |
| Lambert, ML; Roberfroid, D; Vlayen, J | 1 |
| Shapiro, H; Singer, P | 1 |
| Bennett, AJ; Kendall, DA; O'Sullivan, SE; Randall, MD | 1 |
| Roberfroid, D | 1 |
| Girard, J; Lafontan, M; Piazza, PV | 1 |
| Scheen, AJ; Van Gaal, LF | 3 |
| Krentz, AJ | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Anthenelli, RM | 1 |
| Jensen, MD | 1 |
| Watson, KE | 1 |
| Pfeiffer, AF | 1 |
| Roussel, R | 1 |
| Bodary, PF; Eitzman, DT; Iglay, HB | 1 |
| Cannon, CP; Dibble, CT; Gelfand, EV | 1 |
| McCall, AL | 1 |
| Feinglos, MN; Green, JB | 1 |
| Després, JP; Mancia, G; Pi-Sunyer, X; Ruilope, LM; Scheen, A; Van Gaal, L; Zanchetti, A | 1 |
| Nilsson, PM | 1 |
| Cota, D | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Nogueiras, R; Rohner-Jeanrenaud, F; Tschöp, MH; Woods, SC | 1 |
32 review(s) available for sr141716 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Obesity drug therapy.
Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Combinations; Exercise Therapy; Fructose; Gastrointestinal Hormones; Humans; Incretins; Insulin; Insulin Secretion; Intestines; Lactones; Leptin; Life Style; Models, Biological; Neuropeptides; Obesity; Orlistat; Phentermine; Phytotherapy; Piperidines; Plant Preparations; Pyrazoles; Rimonabant; Topiramate | 2013 |
Pharmacotherapy for obesity in menopausal women.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms | 2008 |
Inhibitors of cannabinoid receptors and glucose metabolism.
Topics: Animals; Blood Glucose; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant | 2008 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
[CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Recent advances in the management of type 2 diabetes mellitus: a review.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Incretins; Piperidines; Pyrazoles; Rimonabant | 2008 |
Pleiotropic effects of rimonabant: clinical implications.
Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors | 2009 |
Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult | 2009 |
The endocannabinoid system: a promising target for the management of type 2 diabetes.
Topics: Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Hypoglycemic Agents; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Topics: Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycated Hemoglobin; Humans; Lipid Metabolism; Metabolic Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2009 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones | 2005 |
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain | 2006 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation | 2006 |
Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
Topics: Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Lipids; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
New oral agents for type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Troglitazone | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Topics: Adipocytes; Adiponectin; Animals; Appetite Regulation; Arachidonic Acids; Cannabinoid Receptor Modulators; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dronabinol; Eating; Endocannabinoids; Energy Metabolism; Humans; Lipid Metabolism; Obesity; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Cardiovascular disease under the influence of excess visceral fat.
Topics: Adiponectin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Prospective Studies; Pyrazoles; Rimonabant; Risk Factors | 2007 |
What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Waist-Hip Ratio | 2007 |
Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss | 2007 |
Adipose tissue and diabetes therapy: do we hit the target?
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Biological; Piperidines; Pyrazoles; Rimonabant; Sulfonylurea Compounds; Thiazolidinediones; Weight Loss | 2007 |
Strategies to reduce vascular risk associated with obesity.
Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors | 2007 |
Cannabinoid-1 receptor antagonists in type-2 diabetes.
Topics: Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Obesity; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms | 2007 |
Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?
Topics: Bariatric Surgery; Cannabinoids; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Life Style; Multicenter Studies as Topic; Obesity; Piperidines; Power, Psychological; Pyrazoles; Rimonabant; Self Concept; Weight Loss | 2008 |
Role of the endocannabinoid system in energy balance regulation and obesity.
Topics: Adipose Tissue; Animals; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Eating; Endocannabinoids; Energy Metabolism; Humans; Hypothalamus; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reward; Rimonabant | 2008 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Piperidines; Pyrazoles; Rimonabant | 2008 |
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2008 |
The endocannabinoid system and the control of glucose homeostasis.
Topics: Adipose Tissue, White; Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Glucose; Homeostasis; Humans; Liver; Models, Biological; Muscles; Obesity; Pancreas; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Rodentia | 2008 |
9 trial(s) available for sr141716 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2008 |
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Hormone Antagonists; Humans; Insulin; Middle Aged; Obesity; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Young Adult | 2010 |
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Overweight; Patient Satisfaction; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2006 |
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2007 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
[Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Topics: Behavior; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
Topics: Appetite Depressants; Cannabinoids; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Obesity; Overweight; Patient Dropouts; Piperidines; Placebos; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss | 2007 |
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Topics: Adult; Blood Pressure; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2008 |
23 other study(ies) available for sr141716 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; CHO Cells; Cricetulus; Cytokines; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Hypoglycemic Agents; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RAW 264.7 Cells; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Weight Loss | 2019 |
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
Topics: Adiponectin; Adiposity; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; Male; Piperidines; Pyrazoles; Rats; Rats, Inbred OLETF; Receptor, Cannabinoid, CB1; Rimonabant; Rosiglitazone; Thiazolidinediones | 2013 |
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Topics: Animals; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Down-Regulation; Drug Inverse Agonism; Eating; Endocannabinoids; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Mitochondria; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2016 |
[Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms | 2008 |
[The endocannabinoid system].
Topics: Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Europe; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2008 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss | 2008 |
[Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Overweight; Piperidines; Pyrazoles; Rimonabant | 2008 |
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Topics: Animals; Appetite Regulation; Body Weight; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
Topics: Adult; Antidepressive Agents; Body Mass Index; Depressive Disorder; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Prescriptions; Feedback; Female; France; Humans; Insurance, Health, Reimbursement; Logistic Models; Male; Middle Aged; Obesity; Piperidines; Practice Guidelines as Topic; Pyrazoles; Retrospective Studies; Rimonabant | 2011 |
Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression Regulation; Glucose; Insulin Resistance; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Piperidines; Podocytes; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA Interference; RNA, Small Interfering | 2012 |
Food and Drug Administration's Obesity Drug Guidance Document: a short history.
Topics: Adolescent; Adult; Advisory Committees; Aged; Anti-Obesity Agents; Bariatric Medicine; Body Mass Index; Child; Congresses as Topic; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Approval; Drug Discovery; Female; History, 20th Century; History, 21st Century; Humans; Male; Middle Aged; Multicenter Studies as Topic; Obesity; Outcome Assessment, Health Care; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Reference Standards; Rimonabant; Safety-Based Drug Withdrawals; United States; United States Food and Drug Administration | 2012 |
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
Topics: Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Dietary Fats; Energy Intake; Female; Humans; Male; Micronutrients; Middle Aged; Obesity; Piperidines; Pyrazoles; Regression Analysis; Rimonabant; Weight Loss | 2012 |
New options for drug treatment of obesity in patients with Type 2 diabetes.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2005 |
A new "wonder drug"?
Topics: Diabetes Mellitus, Type 2; Humans; Piperidines; Pyrazoles; Rimonabant; United States; Weight Loss | 2005 |
[Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Time Factors; Triglycerides; Weight Loss | 2006 |
Does rimonabant pull its weight for type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2006 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Exercise; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant; Weight Loss | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2007 |
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Topics: Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.
Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |